Insilico Medicine Showcases AI Benchmarking on Antibody Developability Metrics

A LinkedIn post from Insilico Medicine describes the latest entry in its #ScienceAIBench series, focusing on AI-based prediction of antibody developability using chromatography-derived properties. The post highlights benchmarking of multiple large language models on heparin affinity chromatography and hydrophobic interaction chromatography retention times, using Spearman correlation as the evaluation metric.

According to the post, Anthropic’s Sonnet 4.5 and Opus 4.6 models showed the strongest performance on electrostatic, charge-driven HAC predictions, while Grok 4.1 led on the more challenging hydrophobic HIC predictions. The analysis suggests a persistent “predictability gap,” with current models performing substantially better on electrostatic features than on hydrophobic aggregation risk, and notes that several prominent models delivered near-random or negatively correlated rankings.

For investors, the post indicates that Insilico Medicine is positioning itself as an independent evaluator of AI capabilities in biologics developability, a strategically relevant niche for AI-driven drug discovery. Demonstrating rigorous benchmarking around antibody properties could enhance the company’s credibility with biopharma partners and potentially support future monetization of internal platforms or collaborations centered on biologics design and optimization.

The emphasis on model performance differentiation also underscores that AI model selection may materially influence outcomes in biologics R&D workflows. If Insilico leverages these insights to refine its own pipelines or to guide partner choices, it could strengthen its competitive position in the emerging market for AI-first drug discovery and antibody engineering, though the post does not provide direct revenue or customer metrics that would clarify near-term financial impact.